BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 28460442)

  • 21. Quantitative reverse transcription-polymerase chain reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with neuroendocrine features.
    Westerman BA; Neijenhuis S; Poutsma A; Steenbergen RD; Breuer RH; Egging M; van Wijk IJ; Oudejans CB
    Clin Cancer Res; 2002 Apr; 8(4):1082-6. PubMed ID: 11948117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR.
    Yang H; Wang R; Peng S; Chen L; Li Q; Wang W
    Oncotarget; 2016 Mar; 7(13):16273-81. PubMed ID: 26919104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers.
    Augustyn A; Borromeo M; Wang T; Fujimoto J; Shao C; Dospoy PD; Lee V; Tan C; Sullivan JP; Larsen JE; Girard L; Behrens C; Wistuba II; Xie Y; Cobb MH; Gazdar AF; Johnson JE; Minna JD
    Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14788-93. PubMed ID: 25267614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
    Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS
    Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
    Li J; Zhang L; Zhu H; Pan W; Zhang N; Li Y; Yang M
    DNA Cell Biol; 2018 Nov; 37(11):903-908. PubMed ID: 30277797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Expression and clinicopathologic significance of human achaete-scute homolog 1 in pulmonary neuroendocrine tumors].
    Li F; Zhong Z; Li R; Huang H; Wang L; Zheng D; Zhang D
    Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):317-21. PubMed ID: 20677557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Significance of MMP-1 in EGFR-TKI-Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting.
    Saito R; Miki Y; Ishida N; Inoue C; Kobayashi M; Hata S; Yamada-Okabe H; Okada Y; Sasano H
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29463039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reciprocal Negative Regulation between EGFR and DEPTOR Plays an Important Role in the Progression of Lung Adenocarcinoma.
    Zhou X; Guo J; Ji Y; Pan G; Liu T; Zhu H; Zhao J
    Mol Cancer Res; 2016 May; 14(5):448-57. PubMed ID: 26896556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
    Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
    Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis.
    Zhang S; Yan B; Zheng J; Zhao J; Zhou J
    Oncotarget; 2016 Sep; 7(39):63758-63766. PubMed ID: 27563816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences of molecular expression mechanisms among neural cell adhesion molecule 1, synaptophysin, and chromogranin A in lung cancer cells.
    Kashiwagi K; Ishii J; Sakaeda M; Arimasu Y; Shimoyamada H; Sato H; Miyata C; Kamma H; Aoki I; Yazawa T
    Pathol Int; 2012 Apr; 62(4):232-45. PubMed ID: 22449227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PGE2/EP3/SRC signaling induces EGFR nuclear translocation and growth through EGFR ligands release in lung adenocarcinoma cells.
    Bazzani L; Donnini S; Finetti F; Christofori G; Ziche M
    Oncotarget; 2017 May; 8(19):31270-31287. PubMed ID: 28415726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
    Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
    Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidermal growth factor receptor tyrosine kinase defines critical prognostic genes of stage I lung adenocarcinoma.
    Yamauchi M; Yamaguchi R; Nakata A; Kohno T; Nagasaki M; Shimamura T; Imoto S; Saito A; Ueno K; Hatanaka Y; Yoshida R; Higuchi T; Nomura M; Beer DG; Yokota J; Miyano S; Gotoh N
    PLoS One; 2012; 7(9):e43923. PubMed ID: 23028479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma.
    Popat S; Wotherspoon A; Nutting CM; Gonzalez D; Nicholson AG; O'Brien M
    Lung Cancer; 2013 Apr; 80(1):1-4. PubMed ID: 23312887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic and therapeutic implications of aromatase expression in lung adenocarcinomas with EGFR mutations.
    Kohno M; Okamoto T; Suda K; Shimokawa M; Kitahara H; Shimamatsu S; Konishi H; Yoshida T; Takenoyama M; Yano T; Maehara Y
    Clin Cancer Res; 2014 Jul; 20(13):3613-22. PubMed ID: 24803578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. POU domain transcription factor BRN2 is crucial for expression of ASCL1, ND1 and neuroendocrine marker molecules and cell growth in small cell lung cancer.
    Ishii J; Sato H; Sakaeda M; Shishido-Hara Y; Hiramatsu C; Kamma H; Shimoyamada H; Fujiwara M; Endo T; Aoki I; Yazawa T
    Pathol Int; 2013 Mar; 63(3):158-68. PubMed ID: 23530560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative analysis of TTF-1 binding DNA regions in small-cell lung cancer and non-small-cell lung cancer.
    Hokari S; Tamura Y; Kaneda A; Katsura A; Morikawa M; Murai F; Ehata S; Tsutsumi S; Ishikawa Y; Aburatani H; Kikuchi T; Miyazono K; Koinuma D
    Mol Oncol; 2020 Feb; 14(2):277-293. PubMed ID: 31782890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.
    Spitschak A; Meier C; Kowtharapu B; Engelmann D; Pützer BM
    Mol Cancer; 2017 Jan; 16(1):24. PubMed ID: 28122586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RET isoform-specific interaction with scaffold protein Ezrin promotes cell migration and chemotaxis in lung adenocarcinoma.
    Moodley S; Lian EY; Crupi MJF; Hyndman BD; Mulligan LM
    Lung Cancer; 2020 Apr; 142():123-131. PubMed ID: 32146264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.